Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
GlaxoSmithKline PLC Insider Profile
25 Followers
GlaxoSmithKline PLC, Ten Percent Owner at Innoviva, holds 13.98M shares in Wave Life Sciences (Ticker: WVE), holds 0.00 shares in Theravance Biopharma (Ticker: TBPH), holds 1.01M shares in CVRx (Ticker: CVRX). Most recently, GlaxoSmithKline PLC Bought ― shares of Wave Life Sciences on Jan 30, 2024 for an estimated value of 16.50M.
Profitable Transactions
16 out of 37 Profitable Transactions
Average Return
+0.90%
Average return per transaction
Time Frame
Compare to
Insider Holdings
A breakdown of GlaxoSmithKline PLC's holdings
Insider Roles
Roles that GlaxoSmithKline PLC holds in companies
Most Profitable Insider Trade
Stock:
Principia Biopharma
(PRNB)
(PRNB)
Rating:Informative Buy
Date:Oct 22, 2019 - Oct 22, 2020
Return:+222.40%
The most profitable trade made by GlaxoSmithKline PLC
GlaxoSmithKline PLC's Trading History
Innoviva
May 24, 2021
Ten Percent Owner
Informative Sell
392.06M
$0.00
Spero Therapeutics
Jul 17, 2018
Ten Percent Owner
Informative Buy
1.00M
$2.82M
Liquidia Technologies
Aug 01, 2018
Former 10% holder
Uninformative Buy
―
$7.82M
Principia Biopharma
Oct 22, 2019
―
Informative Buy
10.00M
$298.43M
Turning Point Therapeutics
May 26, 2020
―
Informative Buy
5.00M
$171.30M
Fulcrum Therapeutics
Jul 24, 2019
Ten Percent Owner
Uninformative Buy
―
$12.75M
Progyny
May 21, 2020
Ten Percent Owner
Informative Sell
103.00M
$199.87M
Bicycle Therapeutics
Sep 18, 2020
Ten Percent Owner
Informative Sell
91.81K
$43.43M
Nkarta
Jul 16, 2020
Director, Ten Percent Owner
Uninformative Buy
―
$21.65M
Pandion Therapeutics
Jul 22, 2020
―
Uninformative Buy
―
$135.01M
Decibel Therapeutics
Feb 19, 2021
―
Uninformative Buy
―
$5.81M
Lyell Immunopharma
Jun 23, 2021
Ten Percent Owner
Uninformative Buy
―
$65.65M
CVRx
Jul 06, 2021
Ten Percent Owner
Uninformative Buy
―
$14.80M
Wave Life Sciences
Jan 30, 2024
Ten Percent Owner
Informative Buy
16.50M
$65.16M
Theravance Biopharma
Sep 20, 2022
Former 10% Owner
Uninformative Sell
94.04M
$0.00
Applied Genetic Technologies
Feb 24, 2015
―
Informative Sell
11.07M
$564.52K
HTG Molecular Diagnostics
Mar 29, 2017
Ten Percent Owner
Informative Sell
3.04M
$356.74K
Anacor Pharmaceuticals
Nov 24, 2010
―
Informative Buy
5.00M
$450.10M
ChemoCentryx
Oct 18, 2018
―
Informative Sell
85.85M
$0.00
OncoMed Pharma
Jul 23, 2013
―
Uninformative Buy
―
$2.32M
Concert Pharma
Feb 20, 2014
―
Uninformative Buy
―
$11.35M
Genocea Biosciences
Jul 30, 2020
Ten Percent Owner
Informative Buy
2.84M
$69.40K
Response Genetics
Sep 21, 2012
Ten Percent Owner
Informative Buy
―
$70.00K
Amicus
Oct 28, 2014
Former 10% Owner (1)
Informative Sell
59.86M
$0.00
Maxygen
Jan 04, 2010
―
Informative Sell
27.14M
―
Nupathe Inc
Feb 24, 2014
―
Informative Buy
3.00M
―
Quest Diagnostics
Feb 02, 2011
Director, Ten Percent Owner
Informative Sell
1.69B
$0.00
List of latest transactions for each holding click on a transaction to see GlaxoSmithKline PLC's performance on stock
You May Also Like
GlaxoSmithKline PLC insider profile FAQ
What is the percentage of profitable transactions made by GlaxoSmithKline PLC?
The percentage of profitable transactions made by GlaxoSmithKline PLC is 43%.
What is the average return per transaction made by GlaxoSmithKline PLC?
The average return per transaction made by GlaxoSmithKline PLC is 0.90%.
What stocks does GlaxoSmithKline PLC hold?
GlaxoSmithKline PLC holds: INVA, SPRO, LQDA, PRNB, TPTX, FULC, PGNY, BCYC, NKTX, PAND, DBTX, LYEL, CVRX, WVE, TBPH, AGTC, HTGMQ, ~ANAC, CCXI, OMED, CNCE, GNCAQ, RGDXQ, FOLD, MAXY, ~PATH, DGX stocks.
What was GlaxoSmithKline PLC’s latest transaction?
GlaxoSmithKline PLC latest transaction was an Informative Buy of $16.50M.
What was GlaxoSmithKline PLC's most profitable transaction?
GlaxoSmithKline PLC’s most profitable transaction was an Informative Buy of PRNB stock on October 22, 2019. The return on the trade was 222.40%.
What is GlaxoSmithKline PLC's role in Innoviva?
GlaxoSmithKline PLC's role in Innoviva is Ten Percent Owner.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.